- The bioMérieux Share
- Regulated Information
- Shareholder area
Organic growth of 19.4% at constant exchange rates and scope of consolidation over the first nine months of the year.
Further exceptional momentum in the third quarter (+26.5%) driven by the molecular biology lines
2020 outlook: sales growth >16%. cEBIT >520 m€
« Fighting the pandemic is a priority for bioMérieux. Our employees and our resources are fully mobilized in this fight, in order to fulfill our public health commitment » Alexandre Mérieux - Chairman & CEO